Clinical predictors of thiopurine-related adverse events in Crohn's disease
Gordon W Moran, Marie-France Dubeau, Gilaad G Kaplan, Hong Yang, Bertus Eksteen, Subrata Ghosh, Remo Panaccione, Inflammatory Bowel Disease Clinic, Division of Gastroenterology, Department of Medicine, Cumming School of Medicine, University of Calgary, Alberta T2N 1N4, Canada
Gordon W Moran, Nottingham Digestive Diseases Centre, Biomedical Research Unit, University of Nottingham, NG7 2UH Nottingham, United Kingdom
Gilaad G Kaplan, Hong Yang, Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta T2N 1N4, Canada
Author contributions: Moran GW, Dubeau MF, Kaplan GG, Ghosh S and Panaccione R conceived the study; Moran GW and Dubeau MF extracted the phenotypic data; Moran GW, Dubeau MF, Kaplan GG, Yang H and Eksteen B analysed the data; Moran GW and Dubeau MF drafted the manuscript; Dubeau MF, Kaplan GG, Yang H, Eksteen B, Ghosh S and Panaccione C critically appraised the manuscript; Moran GW prepared the final manuscript; and Dubeau MF, Kaplan GG, Yang H, Eksteen B, Ghosh S and Panaccione R approved the final version.
Ethics approval: The study was approved by the Conjoint Health Research Ethics Board of the University of Calgary.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: Gordon W Moran has received consultancy fees from Abbvie and financial support for educational activities from Abbvie, MSD, Merck Sharp and Dohme Ltd and Ferring. Gilaad G Kaplan has served as a speaker for Merck, Schering-Plough, Jansen, and Abbott. He has participated in advisory board meetings for Abbott, Merck, Schering-Plough, Shire, Jansen, and UCB Pharma. Dr Kaplan has received research support from Abbott, Merck, and Shire. Subrata Ghosh has served as a speaker for Merck, Schering-Plough, Centocor, Abbott, UCB Pharma, Pfizer, Ferring, and Procter and Gamble. He has participated in ad-hoc advisory board meetings for Centocor, Abbott, Merck, Schering-Plough, Proctor and Gamble, Shire, UCB Pharma, Pfizer, and Millennium. He has received research funding from Procter and Gamble, Merck, and Schering-Plough. Remo Panaccione has served as a speaker, a consultant and an advisory board member for Abbott Laboratories, Merck, Schering-Plough, Shire, Centocor, Elan Pharmaceuticals, and Procter and Gamble. He has served as a consultant and speaker for Astra Zeneca. He has served as a consultant and an advisory board member for Ferring and UCB. He has served as a consultant for Glaxo-Smith Kline and Bristol Meyers Squibb. He has served as a speaker for Byk Solvay, Axcan, Jansen, and Prometheus. He has received research funding from Merck, Schering-Plough, Abbott Laboratories, Elan Pharmaceuticals, Procter and Gamble, Bristol Meyers Squibb, and Millennium Pharmaceuticals. He has received educational support from Merck, Schering-Plough, Ferring, Axcan, and Jansen. The remaining authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Gordon W Moran, Clinical Associate Professor, Honorary Consultant Gastroenterologist, Nottingham Digestive Diseases Centre, Biomedical Research Unit, University of Nottingham, Queen’s Medical Centre, E floor, West Block, NG7 2UH Nottingham, United Kingdom. firstname.lastname@example.org
Telephone: +44-115-9249924-70608 Fax: +44-115-8231409
Received: October 28, 2014
Peer-review started: October 29, 2014
First decision: December 11, 2014
Revised: January 10, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: July 7, 2015